中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (8): 641-647.doi: 10.19401/j.cnki.1007-3639.2017.08.007

• 论著 • 上一篇    下一篇

过氧化物还原酶Ⅱ在胃癌中的表达及临床病理意义

牛林军1,徐 浩1,马高磊1,顾玉明2   

  1. 1. 徐州医科大学研究生学院,江苏 徐州 221004 ;
    2. 徐州医科大学附属医院介入放射科,江苏 徐州 221002
  • 出版日期:2017-08-30 发布日期:2017-09-21
  • 通信作者: 顾玉明 E-mail: guyuming_2006@163.com

Expression and clinicopathologic significance of peroxiredoxin Ⅱ in gastric cancer

NIU Linjun1, XU Hao1, MA Gaolei1, GU Yuming2   

  1. 1. Graduate School, Xuzhou Medical College, Xuzhou 221004, Jiangsu Province, China; 2. Department of Interventional Radiology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou 221002, Jiangsu Province, China
  • Online:2017-08-30 Published:2017-09-21
  • Contact: GU Yuming E-mail: guyuming_2006@163.com

摘要: 背景与目的:过氧化物还原酶Ⅱ(peroxiredoxin Ⅱ,PrxⅡ)是具有过氧化物酶活性的蛋白,相关研究提示其参与多种恶性肿瘤的发生、发展。该实验通过研究人类胃癌组织及细胞中的PrxⅡ的表达情况,分析其与胃癌临床病理特征的关系,探讨其与胃癌发生、发展及预后的关系。方法:采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,RTFQ-PCR)和蛋白[质]印迹法(Western blot)检测45例胃癌患者的癌组织及相应的癌旁组织、胃正常细胞(GES-1)及胃腺癌细胞(MGC-803、MKN-45和MKN-28)的PrxⅡ mRNA及蛋白表达情况。应用免疫组织化学S-P法检测胃癌组织芯片中116例胃癌患者癌组织及癌旁组织的Prx Ⅱ的表达量,分析Prx Ⅱ表达与胃癌临床病理特征的关系并做生存分析。结果:RTFQ-PCR和Western blot检测结果显示,胃癌组织中PrxⅡ mRNA及蛋白表达水平明显高于相应的癌旁组织(P<0.05)。胃癌细胞中PrxⅡ mRNA及蛋白表达水平明显高于胃正常细胞(P<0.01)。免疫组织化学结果显示,胃癌组织中PrxⅡ蛋白的表达阳性率(76.7%)同样明显高于相应癌旁组织(30.1%,P<0.01)。PrxⅡ蛋白表达与胃癌的肿瘤大小、分化程度、浸润深度、TNM分期及淋巴结转移密切相关(P<0.05),而与患者的性别、年龄、肿瘤部位及远处转移无关(P>0.05)。PrxⅡ蛋白高表达者的生存时间要显著低于低表达者(P<0.01),Prx Ⅱ是影响胃癌预后的独立危险因素。结论:PrxⅡ促进胃癌的发生、发展,是胃癌的不良预后因素,其研究可能为胃癌的治疗提供新的靶点。

关键词: 过氧化物还原酶Ⅱ, 胃癌, 实时荧光定量聚合酶链反应, 组织芯片

Abstract: Background and purpose: Peroxiredoxin Ⅱ (PrxⅡ) has the activity of peroxidase. The relevant studies found it played an important role in gastric cancer. This study aimed to investigate the expression of PrxⅡ in human gastric cancer tissues and cells, analyze its relationship with clinicopathological characteristics, and explore the relationship between PrxⅡ and the prognosis and the development of gastric cancer. Methods: The expression of PrxⅡ mRNA and protein in gastric cancer tissues and the paired adjacent normal tissues from 45 patients was detected by real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) and Western blot. The same methods were used to detect the expression of PrxⅡ mRNA and protein in GES-1, MGC-803, MKN-45 and MKN-28. Tissue microarray and immunohistochemistry were used to detect the expression of PrxⅡ protein in gastric cancer tissues and the paired adjacent normal tissues from 116 patients. The relationship between the results and clinicopathological characteristics was analyzed. The prognosis was analyzed. Results: According to results of RTFQ-PCR and Western blot, we found that PrxⅡ mRNA and protein in gastric cancer tissues were significantly higher than that in adjacent normal tissues (P<0.05). PrxⅡ mRNA and protein in gastric cancer cells were higher than that in normal gastric cells (P<0.01). Immunohistochemistry revealed that the expression of PrxⅡ protein in gastric cancer tissues (76.7%) was also significantly higher (P<0.01) than that in adjacent normal tissues (30.1%). The expression of PrxⅡ protein is significantly related to tumor size, histological differentiation, depth of invasion, TNM stage and lymph node metastasis (P<0.05), but had no significant relationship with the gender, age, tumor location and distant metastasis. Survival in patients with higher PrxⅡ expression significantly shorter than in those with lower expression (P<0.01). PrxⅡ is an independent prognostic factor of gastric cancer (P<0.05). Conclusion: PrxⅡ promotes the development of gastric cancer. It is one of the adverse prognostic factors of gastric cancer and may serve as a new therapeutic target for gastric cancer.

Key words: Peroxiredoxin Ⅱ, Gastric cancer, Real-time fluorescent quantitative polymerase chain reaction, Tissue microarray